Merck ends development of Parkinson's disease drug
WHITEHOUSE STATION, N.J. Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Merck (MRK) says it reviewed initial data from three late-stage clinical trials and did not find evidence preladenant was more effective than a placebo.
- FDA raises concerns about experimental sleep aid suvorexant
- Eating nicotine-containing like peppers, tomatoes may lower Parkinson's risk
The company says it doesn't plan to file for marketing approval of the drug. It says the decision was not related to any safety problems.
Shares of Merck rose 62 cents to $47.33 on Thursday. The stock lost 21 cents, to $47.12, in after-hours trading.